Adial Pharmaceuticals Inc... (ADILW)
Adial Pharmaceuticals WT EXP 073123 Statistics
Share Statistics
Adial Pharmaceuticals WT EXP 073123 has - shares outstanding. The number of shares has increased by null% in one year.
| Shares Outstanding | - |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | - |
| Failed to Deliver (FTD) Shares | - |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -1.42 and the forward PE ratio is null. Adial Pharmaceuticals WT EXP 073123's PEG ratio is 0.02.
| PE Ratio | -1.42 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 4.62 |
| P/FCF Ratio | -2.71 |
| PEG Ratio | 0.02 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Adial Pharmaceuticals WT EXP 073123.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.16, with a Debt / Equity ratio of 0.
| Current Ratio | 4.16 |
| Quick Ratio | 4.16 |
| Debt / Equity | 0 |
| Debt / EBITDA | 0 |
| Debt / FCF | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $- |
| Profits Per Employee | $- |
| Employee Count | undefined |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is 0, so Adial Pharmaceuticals WT EXP 073123's price volatility has been lower than the market average.
| Beta | 0 |
| 52-Week Price Change | null% |
| 50-Day Moving Average | 0.02 |
| 200-Day Moving Average | 0.17 |
| Relative Strength Index (RSI) | 39.3 |
| Average Volume (20 Days) | - |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -8.28M |
| Net Income | -13.2M |
| EBITDA | -8.28M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -0.71 |
Balance Sheet
The company has 3.75M in cash and 0 in debt, giving a net cash position of 3.75M.
| Cash & Cash Equivalents | 3.75M |
| Total Debt | 0 |
| Net Cash | 3.75M |
| Retained Earnings | -82M |
| Total Assets | - |
| Working Capital | - |
Cash Flow
In the last 12 months, operating cash flow was -6.92M and capital expenditures 0, giving a free cash flow of -6.92M.
| Operating Cash Flow | -6.92M |
| Capital Expenditures | 0 |
| Free Cash Flow | -6.92M |
| FCF Per Share | -0.37 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ADILW does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for ADILW.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | null |
| Piotroski F-Score | null |